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Inflammatory autoimmune diseases such as mul-
tiple sclerosis (MS), inflammatory bowel disease 
(IBD), and psoriasis are a major health burden 
especially  in  industrialized  countries,  affecting 
up to 5% of the population. Genetic analyses, 
functional data, and experimental animal studies 
showed that these diseases have aberrant induc-
tion of IL-12–producing DCs and IFN-+ Th1 
cells as well as IL-23–producing DCs and IL-17+ 
Th17  cells,  whereas  IL-4  is  virtually  absent 
(Frohman et al., 2006; Burton et al., 2007; Nair 
et al., 2009; Nestle et al., 2009). Despite these 
insights, treatment of inflammatory autoimmune 
diseases remains challenging, and their differential 
response to novel therapies is largely unex-
plained. Relapsing MS is attenuated by IFN- 
(Frohman et al., 2006; Axtell et al., 2010) or in-
hibitors of T cell migration (Polman et al., 2006), 
whereas anti–IL-12/IL-23p40 mAb did not im-
prove MS (Segal et al., 2008). In contrast, anti–
IL-12/IL-23p40  mAb  improves  psoriasis  and 
psoriatic arthritis (Krueger et al., 2007). Simi-
larly, TNF inhibitors improve psoriasis, psoriatic 
arthritis, and IBD, whereas they exacerbate MS 
(Frohman et al., 2006; Kneilling et al., 2009). 
Thus, even though MS, psoriasis, and IBD as 
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Fumarates improve multiple sclerosis (MS) and psoriasis, two diseases in which both IL-12 
and IL-23 promote pathogenic T helper (Th) cell differentiation. However, both diseases 
show opposing responses to most established therapies. First, we show in humans that 
fumarate treatment induces IL-4–producing Th2 cells in vivo and generates type II den-
dritic cells (DCs) that produce IL-10 instead of IL-12 and IL-23. In mice, fumarates also 
generate type II DCs that induce IL-4–producing Th2 cells in vitro and in vivo and protect 
mice from experimental autoimmune encephalomyelitis. Type II DCs result from fumarate-
induced glutathione (GSH) depletion, followed by increased hemoxygenase-1 (HO-1)  
expression and impaired STAT1 phosphorylation. Induced HO-1 is cleaved, whereupon the 
N-terminal fragment of HO-1 translocates into the nucleus and interacts with AP-1 and 
NF-B sites of the IL-23p19 promoter. This interaction prevents IL-23p19 transcription 
without affecting IL-12p35, whereas STAT1 inactivation prevents IL-12p35 transcription 
without affecting IL-23p19. As a consequence, GSH depletion by small molecules such as 
fumarates induces type II DCs in mice and in humans that ameliorate inflammatory auto-
immune diseases. This therapeutic approach improves Th1- and Th17-mediated autoimmune 
diseases such as psoriasis and MS by interfering with IL-12 and IL-23 production.
©  2011  Ghoreschi  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first 
six months after the publication date (see http://www.rupress.org/terms). After   
six  months  it  is  available  under  a  Creative  Commons  License  (Attribution– 
Noncommercial–Share  Alike  3.0  Unported  license,  as  described  at  http:// 
creativecommons.org/licenses/by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e2292 Fumarates induce protective type II DCs | Ghoreschi et al.
that produced IL-10 instead of IL-12 and IL-23. The genera-
tion of type II DCs by fumarates induced GATA3-expressing 
Th2 cells, in vitro and in vivo, and protected mice from devel-
oping experimental autoimmune encephalomyelitis (EAE).
RESULTS
Fumarate therapy induces IL-4–producing CD4+  
T cells in humans
Clinical trials demonstrated the efficacy of DMF therapy in 
MS (Kappos et al., 2008) and psoriasis (Altmeyer et al., 
1994). To  study  the  effects  of  DMF  therapy  on  human   
autoimmune diseases share some immunological similarities, a 
common therapeutic agent is still lacking.
Dimethylfumarate (DMF) is a small molecule that is ap-
proved as a combination with the structurally related mono-
methylfumarate (MMF) for the treatment of psoriasis in some 
countries. Prospective phase II trials demonstrated that treat-
ment with DMF is effective in both psoriasis (Altmeyer et al., 
1994; Ghoreschi et al., 2003a) and MS (Kappos et al., 2008). 
Consequently, DMF is one of the first small molecules that 
directly improve the two autoimmune diseases, psoriasis and   
MS, which are both associated with pathogenic Th1 and Th17 
cells; yet the mechanisms underlying the therapeutic efficacy 
remain undefined.
Some studies have implicated fumarates in DCs and Th 
cell survival or differentiation (de Jong et al., 1996; Litjens et al., 
2004); others suggest a mode of action that is not related to 
immunity (Loewe et al., 2002; Kappos et al., 2008). No data 
exist on direct ex vivo analysis of DCs or T cells from either 
mice or humans treated with fumarates; data from a small 
number of psoriasis patients treated with a DMF/MMF- 
containing formulation suggest that fumarates favor Th2 devel-
opment, yet the data did not provide a definitive conclusion 
(Litjens et al., 2003). The exact mechanisms leading to the 
improvement of MS remain unexplained (Kappos et al., 2008).   
Structurally, DMF is an ,-unsaturated carboxylic acid ester 
that binds glutathione (GSH), the cell’s most important scav-
enger of reactive oxygen species (ROS). Thus, despite con-
flicting data (Mrowietz and Asadullah, 2005), DMF depletes 
intracellular stores of GSH most likely by conjugate forma-
tion. This is interesting in the context of genetic linkage ana-
lyses that correlated the risk of high IgE and ROS-aggravated 
type I allergy to distinct GST (GSH S-transferase) genotypes 
(Gilliland et al., 2004). As a consequence, GSH metabolism 
may affect the capacity to cope with oxidative stress and as   
a result control the development of either Th1 or Th2 re-
sponses (Jeannin et al., 1995; Gilliland et al., 2004). This explana-
tion  is  in  agreement  with  independent  data  correlating 
intracellular  ROS  concentrations with IL-12 production by 
DCs (Peterson et al., 1998). The therapeutic success of fuma-
rates in psoriasis and MS on one side and the potential im-
mune modulation caused by oxidative stress on the other may 
both result from the depletion of GSH, the common target 
molecule of fumarates.
To test this hypothesis, we analyzed the effects of fuma-
rates on human and mouse immune responses in vitro and   
in vivo, focusing on DCs and their impact on Th cell differ-
entiation. DMF treatment of DCs diminished intracellular 
GSH stores by 50%, increased hemoxygenase-1 (HO-1) lev-
els, and inhibited phosphorylation of STAT1 in activated DCs. 
Surprisingly, STAT1 activation and, downstream, IFN con-
sensus sequence-binding protein (ICSBP/IRF-8) signaling was 
required for IL-12p35 transcription but not for IL-23p19. 
In contrast, induction of HO-1 impaired IL-23p19 expres-
sion, without affecting IL-12p35. As a consequence, GSH de-
pletion generated type II DCs (Menges et al., 2002; Schuler 
et al., 2003; Mazzoni and Segal, 2004; Dudziak et al., 2007) 
Figure 1.  DMF therapy induces Th2 responses in human CD4+ T cells 
in vivo and human type II DCs. (A) CD4+ T were isolated from patients with 
psoriasis treated with either DMF or placebo at the indicated time of therapy 
and treated with PMA and ionomycin. IL-2, IL-4, and IFN- were assessed by 
intracellular flow cytometry. Each data point represents an individual patient 
sample (*, P < 0.05; **, P < 0.01). Horizontal bars represent the mean.  
(B) Quantification of intracellular GSH content of DCs treated with DMSO,  
70 µM DMF, or 70 µM DMF and 1 mM GSH-OEt. Results are pooled data from 
four human donors (mean ± SEM; **, P < 0.01). (C–E) Human DCs were incu-
bated with DMSO, 70 µM DMF, or DMF + 1 mM GSH-OEt and then treated 
with LPS for 18 h. IL-12, IL-23, or IL-10 production was determined by ELISA. 
Data were pooled from three donors (mean ± SEM; *, P < 0.05; **, P < 0.01).JEM Vol. 208, No. 11 
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Fumarate-mediated induction of mouse type II macrophages 
and type II DCs
To precisely analyze the effects of DMF in vitro and in vivo, 
we  investigated  the  role  of  DMF  in  mice.  We  analyzed 
DMF-mediated GSH depletion in DCs, macrophages, and   
T cells of mice and in an animal model of Th1- and Th17-
mediated disease, EAE. DMF depleted GSH in BM-derived 
DCs (BMDCs) of mice to the same extent as in human DCs 
(Fig. 2 A). As observed for human DCs, DMF treatment im-
paired IL-12 and IL-23 production by ≥90%, while signifi-
cantly increasing IL-10 production by mouse DCs (Fig. 2 B). 
We postulated that DMF-mediated modulation of cytokine 
production might be regulated by ROS. We fully restored 
intracellular GSH levels of DMF-treated macrophages or DCs 
with either GSH-OEt or N-acetylcysteine (NAC; Fig. 2 C). 
Replenishing intracellular GSH partially restored the capa-
bility of DCs to make IL-12 or IL-23 (Fig. 2 B). The effects 
were similar to those obtained with human macrophages and 
DCs (Fig. 1, B–E). To ask whether DMF affects cytokine 
production through induction of ROS, we directly exposed 
DCs to H2O2 and stimulated the cells with LPS. H2O2 mir-
rored the DMF-dependent modulation of IL-12, IL-23, or 
IL-10  production  (not  depicted).  Depletion  of  the  ROS 
scavenger GSH with either H2O2 or with DMF had identical 
effects on DC cytokine production; importantly, both were 
fully reversed by GSH-OEt or NAC, directly demonstrating 
the  key  role  of  GSH  in  the  modulation  of  DC  function   
by DMF. Similar results were obtained with a second GSH- 
depleting fumarate, MMF (not depicted).
ROS-mediated inhibition of either IL-12 or IL-23 through 
distinct signaling pathways
ROS may directly regulate various signaling pathways, in-
cluding p38, Nrf2, or HO-1. In agreement with other ex-
perimental conditions (Durchdewald et al., 2007), we found 
no major effect of ROS-mediated GSH depletion on LPS-
induced Nrf2 messenger RNA (mRNA) expression (not de-
picted).  In  contrast,  quantitative  real-time  PCR  (RT-PCR) 
revealed that DMF increased HO-1 expression in LPS-activated 
immune responses, we analyzed the intracellular cytokine 
production of freshly isolated CD4+ and CD8+ T cells from 
19 patients enrolled in a double-blind, placebo-controlled 
trial after 0, 4, and 16 wk of DMF treatment for psoriasis. 
In the DMF-treated group, the percentage of IFN-+CD4+ 
T cells decreased significantly over the entire study period, 
whereas the percentage of IL-4+CD4+ T cells peaked at   
4 wk (Fig. 1 A). This increase of IL-4+CD4+ T cells was 
transient, but the ratio of IL-4/IFN-+ CD4+ T cells sig-
nificantly increased at 4 wk as well as 16 wk of treatment 
(P < 0.05; not depicted). DMF therapy did not affect the 
percentage of IL-2+CD4+ T cells (Fig. 1 A) or the cytokine 
pattern of CD8+ T cells (not depicted). In contrast, in the 
placebo  group,  the  percentage  of  IL-4+CD4+  and  IFN-
+CD4+ T cells (Fig. 1 A) as well as the ratio of both popu-
lations (not depicted) remained stable over time, showing 
that the cytokine changes were specific for CD4+ T cells in 
DMF-treated patients. Consistent with data from previous 
studies, fumarate-mediated inhibition of Th1 cells and the 
induction of Th2 cells correlated with the clinical improve-
ment of psoriasis (not depicted; Ghoreschi et al., 2003a,b; 
Litjens et al., 2003).
Fumarate-mediated induction of human type II DCs
As DMF forms conjugates with GSH, DMF should diminish 
intracellular GSH levels. Because of the conflicting published 
data (Mrowietz and Asadullah, 2005), we first determined the 
effects of DMF on GSH levels in human DCs and macro-
phages. Therapeutic  DMF  concentrations  depleted  intra-
cellular GSH by 50%; GSH levels were fully restored by the 
cell-permeable  ROS  scavenger  GSH-OEt  (GSH  reduced 
ethyl ester; Fig. 1 B). Simultaneously, DMF impaired the capacity 
of DCs or macrophages to produce either IL-12 (Fig. 1 C) or 
IL-23 (Fig. 1 D) in response to the TLR4 ligand LPS. In con-
trast, their capacity to produce IL-10 was slightly, but sig-
nificantly increased (P < 0.05; Fig. 1 E). Thus, DMF may 
promote type II DCs. In contrast to the effects of fuma-
rates on DCs, fumarates had no detectable effect on purified   
T cells (not depicted).
Figure 2.  DMF induces mouse type II macro-
phages and type II DCs. (A) BMDCs were incu-
bated with DMSO, 70 µM DMF, or DMF + 1 mM 
GSH-OEt, and GSH content was determined by a 
colorimetric assay (mean ± SEM; *, P < 0.001).  
(B) DCs were treated with DMSO, 70 µM DMF, or 
DMF + 1 mM GSH-OEt and then stimulated with 
LPS for 18 h. Culture supernatants were harvested, 
and the indicated cytokines were determined by 
ELISA (mean ± SEM; *, P < 0.01; **, P < 0.001).  
(C) DCs were incubated with DMSO, 70 µM DMF, 
DMF + 1 mM GSH-OEt, or DMF and 1 mM NAC for 
2–4 h, and intracellular ROS levels were assessed 
by staining with 2’,7’dichlorofluorescein. Intra-
cellular ROS, gray; DMSO-treated controls, open. 
One representative experiment of three is shown.2294 Fumarates induce protective type II DCs | Ghoreschi et al.
that HO-1 suppresses IL-23p19 without affecting IL-12p35, 
we used HO-1 (Ad–HO-1–EGFP) or control (Ad-EGFP) 
adenovirus  for  overexpression  of  this  ROS-sensitive  heat 
shock protein in DCs. Infection with HO-1 adenovirus pre-
vented LPS-induced expression of IL-23p19 mRNA, whereas 
LPS-induced  expression  of  IL-12p35  mRNA  was  not   
affected (Fig. S1, A and B). This pronounced effect of HO-1 
on IL-23 was surprising, as HO-1 has not been described as a 
classical transcription factor. Yet, truncated HO-1 lacking a 
C-terminal part has been demonstrated to migrate into the 
nucleus during ROS stress, where it directly modulates the 
activity of transcription factors such as AP-1 or NF-B (Lin 
et  al.,  2007).  We  confirmed  nuclear  translocation  of  the   
N-terminal truncated HO-1 protein in response to DMF- 
induced ROS stress, whereas the C-terminal part remained 
in the cytoplasm (Fig. 3 C).
Next we analyzed whether DMF-induced HO-1 associ-
ates with putative AP-1 and/or NF-B sites that control the 
IL-23p19  promoter  (Carmody  et  al.,  2007;  Mise-Omata   
et al., 2007; Liu et al., 2009). For that purpose, we performed 
chromatin  immunoprecipitation  (ChIP)  assays  using  anti–
HO-1 antibody. Indeed, we detected specific enrichment of 
three defined regions of the IL-23 promoter in DMF-treated 
DCs but not in control DCs (Fig. 3 D). These regions con-
tain  binding  sites  for  either  AP-1  or  NF-B  (RelA  and   
c-Rel). We next explored the effect of HO-1 binding on 
DCs (Fig. 3 A). As HO-1 is a ROS-sensitive heat shock pro-
tein (Keyse and Tyrrell, 1989), we determined the impact   
of HO-1 induction on either IL-12 or IL-23 production.   
To address this point, we transfected DCs with HO-1 small 
interfering RNA (siRNA) before DMF treatment and LPS 
stimulation. HO-1 siRNA simultaneously prevented LPS-
mediated induction of HO-1 in DMF-treated DCs and re-
stored IL-23p19 mRNA expression by DMF-treated DCs 
(Fig.  3,  A  and  B).  Moreover,  it  partly  restored  IL-12/ 
IL-23p40 mRNA transcription (Fig. 3 B) and, as a consequence, 
IL-23 protein production. In sharp contrast, HO-1 siRNA 
had no effect on the expression of IL-12p35 mRNA (Fig. 3 B), 
and IL-12 production remained undetectable. To confirm 
Figure 3.  DMF-induced HO-1 selectively prevents IL-23 induction. 
(A) DCs were treated with DMSO or 70 µM DMF, and HO-1 mRNA expres-
sion was determined by quantitative RT-PCR. HO-1 data were normalized to 
-actin, and HO-1 level in control siRNA–transfected DMF–treated DCs was 
set as 1.0. The results are representative of three independent experiments. 
Error bars represent SEM. (B) HO-1 was knocked down, and levels of IL-12/
IL-23p40, IL-23p19, or IL-12p35 mRNA were determined by RT-PCR. Data 
(mean ± SEM) were normalized to -actin, and message levels in control 
siRNA–transfected DMF-treated DCs were set as 1.0. (C) DCs were treated 
as in A and lysed, and nuclear or cytoplasmic cell extracts were analyzed by 
Western blotting using antibodies directed against C- or N-terminal HO-1 
protein. (D and E) DCs treated as in A were activated with LPS, cross-linked, 
and immunoprecipitated with anti–HO-1 (D) or anti-H3Ac (E). Bound DNA 
was amplified by quantitative PCR for primer sites P1 (AP-1; position 
412–422 bp), P2 (c-Rel; position 560–584 bp), and P3 (RelA/c-Rel; position 
394–406 bp). Data were pooled from four separate experiments and repre-
sent mean ± SEM (*, P < 0.05; **, P < 0.01; ns, not significant).
Figure 4.  Interaction of DMF-induced HO-1 with the NF-B  
p65-binding site directly inhibits IL-23p19 promoter activity.  
(A) RAW246.7 cells were transfected with a reporter construct containing the 
IL-23p19 promoter and treated with the indicated doses of DMF. Lucifer-
ase activity was measured after stimulation with 100 ng/ml LPS for 6 h. 
Data from one representative of two independent experiments are shown. 
Error bars represent SEM. (B) NIH 3T3 cells were transfected with a re-
porter construct containing the IL-23p19 promoter (1 µg/well) alone or 
together with the expression vector for p65 (1 µg/well), as well as the  
HO-1 or the empty control vector at the indicated concentration. Pooled 
data from two separate experiments with duplicates are shown (mean ± 
SEM; *, P < 0.001 relative to the empty vector control). Reporter gene 
data were normalized to the activity of cotransfected -galactosidase.JEM Vol. 208, No. 11 
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factor  binding  to  promoter  elements  of  IL-12/IL-23p40 
(Zhu et al., 2003) and IL-12p35 (Liu et al., 2004). We there-
fore examined the downstream effects of p-STAT1 on IL-12 
and IL-23 induction in DCs. First, DMF prevented LPS- 
mediated induction of ICSBP (at 4 h; Fig. 5 B) and later of   
IL-12p70 expression (Fig. 5 C). The effects resulted from 
DMF-induced oxidative stress, as addition of GSH-OEt fully 
restored the p-STAT1 signaling cascade (Fig. 5 A), including 
expression and production of IL-12 (Fig. 2 B). To determine 
the requirement of p-STAT1 for IL-12p70 and IL-23 pro-
duction, we stimulated STAT1/ DCs with LPS. In agree-
ment  with  published  data  (Gautier  et  al.,  2005),  IL-12 
production was suppressed in activated STAT1/ DCs 
compared with STAT1+/+ DCs (Fig. 5 D). In sharp contrast, 
IL-23  production  and  IL-10  production  were  unaffected   
in  STAT1/  DCs  (Fig.  5  D),  demonstrating  that  the   
p-STAT1–ICSBP signaling cascade was mainly required for 
IL-12 production (Zhu et al., 2003; Liu et al., 2004; Gautier 
et  al.,  2005).  Consequently,  GSH  depletion  by  fumarates   
affected IL-12 and IL-23 production by interfering with two 
distinct signaling pathways, a finding that may explain why 
STAT1/ mice remain fully sensitive to IL-23–dependent 
EAE (Bettelli et al., 2004).
To directly determine whether DMF also affected DC 
function in vivo, we treated mice with DMF at doses equiva-
lent to those used in humans, isolated CD11c+ DCs by posi-
tive sorting from lymph nodes, and stimulated these DCs 
with LPS for cytokine expression and production. Quantita-
tive RT-PCR showed that in vivo treatment with DMF   
affected DC function exactly as it did in vitro. 
DMF treatment in vivo increased HO-1 ex-
pression (Fig. 6 A) and impaired IL-12/IL-
23p40  mRNA  expression  and  IL-12  protein 
expression by DCs (Fig. 6, B and C). Thus, 
GSH depletion and ROS induction by DMF 
inhibited IL-12 and IL-23 production by inter-
fering  with  two  distinct  signaling  pathways: 
histone 3 acetylation (H3Ac) status, which is a characteristic 
positively associated with transcriptional activation. The data 
show that enrichment for HO-1 was associated with a sig-
nificant reduction in H3Ac modification of the IL-23p19 
promoter (Fig. 3 E). As nuclear HO-1 interferes with the 
transcriptional activity of AP-1 or NF-B (Lin et al., 2007), 
our data show that HO-1 interaction most likely negatively 
modulates the transcriptional activity of AP-1 and NF-B on 
the IL-23p19 promoter in DCs. To test whether this inter-
action was functional, we transfected macrophages with an   
IL-23p19 luciferase promoter construct. Treatment of these 
cells with DMF led to a dose-dependent inhibition of the 
LPS-induced IL-23p19 promoter activity (Fig. 4 A). To fur-
ther analyze whether the interaction of HO-1 with NF-B 
p65 directly affects the IL-23p19 promoter, we transfected 
fibroblasts with an IL-23p19 promoter reporter plasmid and 
vectors that contain p65, HO-1, or empty control vector.   
As expected, p65 induced strong reporter activity of the   
IL-23p19 promoter. Importantly, HO-1 but not the empty 
vector dose-dependently inhibited the IL-23p19 promoter 
activity (Fig. 4 B). Together, the data show that fumarate- 
induced HO-1 directly impairs IL-23p19 transcription.
Because  HO-1  induction  has  been  observed  together 
with impaired STAT1 activation in MHC class II+ cells (Chora 
et al., 2007), we asked whether DMF diminishes IL-12p70 
expression through STAT1 signaling. We found that DMF 
inhibited STAT1 phosphorylation (p-STAT1) in activated 
DCs without affecting p38 phosphorylation (Fig. 5 A). Acti-
vated STAT1 directly induces ICSBP/IRF-8, a transcription 
Figure 5.  DMF treatment selectively impairs IL-12 
induction through inhibition of the p-STAT1– 
ICSBP–IL-12 signaling pathway. (A) DCs were treated 
with DMSO, 70 µM DMF, 1 mM GSH-OEt, or DMF +  
GSH-OEt and stimulated for the indicated time with LPS. 
STAT1, p-STAT1, MAPK, and p-p38 MAPK content of cell 
lysates was analyzed by Western blot. (B) DCs were incu-
bated with DMSO or DMF and activated with LPS for 4 h. 
ICSBP expression was assessed by RT-PCR, and data were 
normalized to -actin and expressed as fold increase 
(mean ± SEM; *, P < 0.01). ICSBP level in unstimulated 
cells (0 h) was set as 1.0. (C) DCs were incubated with 
DMSO or 70 µM DMF and stimulated with LPS for the 
indicated times. IL-12 levels in the culture supernatants 
were analyzed by ELISA. Error bars represent SEM.  
(D) DCs from STAT1+/+ or STAT1/ mice were stimulated for 
18 h with LPS. The indicated cytokines in culture super-
natants were analyzed by ELISA. Data from one out of four 
experiments with similar results are shown (mean ± SEM).2296 Fumarates induce protective type II DCs | Ghoreschi et al.
differentiation into either Th1 or Th17 cells. GATA3 re-
mained at background levels (Fig. 7, A and B). In contrast, 
priming of CD4+ T cells with DMF-treated DCs induced 
GATA3 mRNA and protein expression, whereas T-bet or 
ROR-t remained at background levels (Fig. 7, A and B). 
Modulation of GATA3, T-bet, or ROR-t with fumarates 
strictly required DCs, as fumarates affected none of these 
transcription factors in highly purified CD4+ T cells stimu-
lated  with  anti-CD3/anti-CD28  mAb  in  the  absence  of 
APCs (Figs. S3 and S4 A). DMF-treated DCs also primed 
CD4+ T cells to develop a classical Th2 cell phenotype that 
produced IL-4 instead of IFN- or IL-17 (Fig. 7, C and D) 
and  showed  no  increase  in  Foxp3+  T  cells,  regardless  of 
whether T cells were restimulated with APCs and peptide or 
with  anti-CD3/anti-CD28  mAb  (not  depicted).  In  sharp 
contrast, when purified T cells were primed with anti-CD3/
CD28 mAb, the addition of fumarates did not affect Th1, 
Th17, or Th2 cell differentiation (Figs. S3 and S4), confirm-
ing the strict requirement of APCs for the induction of Th2 
cells with fumarates.
Fumarate-induced type II DCs protect against EAE
Type II DCs impair the capacity of autoreactive T cells to in-
duce organ-specific autoimmune disease (Menges et al., 2002; 
Schuler et al., 2003; Weber et al., 2007). As fumarate-induced 
type II DCs share all major features with classical type II DCs, 
fumarate-treated DCs should suppress Th1 and Th17 cell   
development  in  vivo,  promote Th2  cell  development,  and   
abrogate the capacity of T cells to mediate organ-specific auto-
immune diseases such as EAE (Racke et al., 1994; Chora et al., 
2007). We started with the analysis of V8.2 transgenic CD4+ 
T cells from B10.PL mice. V8.2 transgenic CD4+ T cells that 
were stimulated with APCs and Ac1-11 peptide in the pres-
ence of MMF developed a Th2 phenotype and transferred 
only  minimal  disease.  In  contrast, V8.2  transgenic  CD4+  
T cells differentiated in the absence of MMF transferred severe 
EAE (Fig. S5, A and B). We next analyzed in vitro the effects 
of DMF-induced type II DCs on the differentiation of in vivo 
primed CD4+ T cells. We isolated CD4+ T cells from SJL mice 
immunized with PLP139-151 peptide in CFA. When stimu-
lated with peptide and DMSO-treated DCs, these PLP- 
specific CD4+ T cells developed a phenotype composed of 
Th1 and Th17 cells (Fig. S6, A and B) that transferred severe 
EAE (Fig. 7 E). Yet, when primed with DMF-induced type II 
DCs, the PLP-specific CD4+ T cells developed a Th2 pheno-
type (Fig. S6, A and B) that failed to adoptively transfer 
EAE (Fig. 7 E).
Fumarates induce IL-12IL-23 type II DCs in vivo
As DMF improves psoriasis (Altmeyer et al., 1994; Ghoreschi 
et al., 2003a) and MS (Kappos et al., 2008) in humans, we 
analyzed the effects of DMF therapy on APCs, T cell dif-
ferentiation, and EAE in vivo. As predicted by the in vitro 
cell cultures, DMF treatment significantly diminished GSH 
in mice in vivo (Fig. S7 A). To determine the consequences of 
DMF treatment on the development of immune responses 
IL-12p35  expression  required  STAT1  phosphorylation, 
whereas it was independent of HO-1 induction. In sharp con-
trast, ROS-mediated induction of HO-1 suppressed IL-23p19 
mRNA,  and  in  part  IL-12/IL-23p40,  as  demonstrated  by 
HO-1 siRNA. This negative regulation of IL-12 and IL-23 
was shown across several mouse strains (Fig. S2, A and B) and 
for human DCs from multiple donors (Fig. 1, C–E).
Fumarates induce functional type II DCs that promote  
Th2 cell differentiation in vitro
These pronounced effects of fumarates on the production of 
IL-12, IL-23, and IL-10 should affect the capacity of DCs to 
prime CD4+ T cells for differentiation into Th1/Th17 cells 
or into Th2 cells (Biedermann et al., 2001b; Napolitani   
et al., 2005). To test this hypothesis, we stimulated DMF- or 
DMSO-treated DCs with LPS and analyzed their capacity   
to influence the differentiation of naive or in vivo primed 
CD4+ T cells into Th1, Th17, or Th2 cells. We first stimulated 
naive, TCR transgenic CD4+ T cells with OVA peptide and 
DCs, either in the presence or absence of DMF or MMF, 
which is a DMF derivative with comparable effects on DCs 
(not depicted). We first quantified transcription factors that 
determine T cell differentiation. In the absence of DMF, DCs 
induced CD4+ T cells expressing T-bet and ROR-t mRNA 
and  protein,  the  transcription  factors  which  determine   
Figure 6.  Fumarate treatment induces HO-1 in DCs and inhibits 
IL-12/IL-23p40 production by DCs in vivo. (A–C) Mice were treated 
for 5 d with DMF in water or received DMF-free water (control). DCs were 
isolated, positively sorted, and stimulated with LPS for 18 h before ana-
lyzing HO-1 mRNA (A) or IL-12/IL-23p40 mRNA (B) expression by quanti-
tative RT-PCR. RT-PCR data were normalized to -actin levels, and 
expression in control mice was set as 1.0 (open bars). (C) DC isolated from 
DMF-treated or control mice were stimulated with LPS for 18 h, and  
IL-12p70 production was determined by ELISA. All data are shown as 
mean ± SEM and are representative for four independent experiments.JEM Vol. 208, No. 11 
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PLP139-151–specific CD4+ T cells; yet, these CD4 T cells 
released IFN- but no IL-4 (Fig. S7, B and C). Consequently, 
DMF treatment induced functional type II DCs with rele-
vant suppression of IL-12 and IL-23 in vivo (Fig. 8 A).
In vivo induction of autoreactive Th2 cells by fumarate 
therapy protects against EAE
T cell priming during DMF therapy induced PLP-specific 
Th2 cells in vivo. To test whether this influenced the course 
of EAE, we compared the course of EAE in control mice and 
DMF-treated mice. Immunizing control mice with PLP139-
151 in CFA resulted in severe, grade 4 EAE. In sharp con-
trast, DMF-treated mice were highly protected from EAE 
when immunized with PLP139-151 in CFA. Mice developed 
either no or only minimal signs of EAE (Fig. 8 C). Both, 
DMF and MMF treatment similarly protected SJL, B10.PL, 
and C57BL/6 mice from EAE whether we used active or 
passive immunization (not depicted).
To determine whether in vivo priming during fumarate 
treatment induced functional type II DCs that abolished the 
capacity of autoreactive T cells to cause EAE, we performed two 
different sets of experiments: we first asked whether DMF 
requires the induction of IL-4 to suppress EAE and then 
whether  this  suppression  results  from  the  IL-4–producing 
in vivo, we first immunized either DMF-treated or control 
SJL  mice  with  PLP139-151  in  CFA.  On  days  1–3,  we 
quantified IL-12/IL-23p40, IL-12p35, or IL-23p19, T-bet, 
ROR-t, or GATA3 mRNA (Fig. 8, A and B) and, on day 6,   
T cell differentiation in draining lymph nodes. Immunizing 
control mice with PLP139-151 in CFA induced mRNA 
expression  of  IL-12/IL-23p40,  IL-12p35,  and  IL-23p19 
(Fig. 8 A) and of T-bet and ROR-t, whereas GATA3   
remained low (Fig. 8 B). In sharp contrast, immunization   
of DMF-treated mice with PLP139-151 in CFA increased 
GATA3 mRNA ≥40-fold, whereas IL-12/IL-23p40, IL-12p35, 
IL-23p19, T-bet, or ROR-t expression remained close to 
background (Fig. 8, A and B). Importantly, separate analysis 
of DCs and T cells isolated from DMF-treated nonimmu-
nized mice had shown that DMF targeted the differentia-
tion of DCs but not of T cells (Fig. 6 and not depicted). 
Intracellular cytokine staining and ELISPOT assays demon-
strated that PLP139-151–specific CD4+ T cells from DMF-
treated  immunized  mice  were  Th2  cells,  whereas  CD4+  
T cells from immunized control mice showed a Th1 or Th17 
phenotype (Fig. S7, B and C). These Th2 cells produced 
IL-4 but no IFN-, regardless of whether they were stimu-
lated with PMA and ionomycin or with peptide and APCs. 
Controls  had  equivalent  numbers  of  cytokine-producing 
Figure 7.  Type II DCs resulting from fuma-
rate treatment selectively induce Th2 cells 
in vitro. (A) Naive OVA-specific CD4+ T cells 
were left unstimulated (gray bars) or were 
primed in vitro with OVA peptide and LPS- 
activated, DMSO-treated (open bars), or DMF-
treated (black bars) DCs. Expression of the 
indicated transcription factors was assessed by 
RT-PCR, and the data were normalized to  
-actin. Expression levels in unstimulated T cells 
were set at 1.0 (gray bars). Data are representa-
tive of three independent experiments (mean ± 
SEM; *, P < 0.05; **, P < 0.01). (B) DCs were 
treated and activated as in A and incubated 
alone (left lane) or with OVA-specific CD4+  
T cells (middle and right lanes). T-bet or GATA3 
protein expression in cell extracts was analyzed 
by Western blotting. (C and D) Naive OVA-specific 
CD4+ T cells were primed in vitro with OVA 
peptide and LPS-activated APCs in the presence 
or absence of DMF. Cells were expanded for 1 wk  
and then restimulated with OVA peptide and 
fresh APCs. Cytokines were determined by intra-
cellular cytokine staining and flow cytometry (C) 
or by ELISA (D). Data from one representative 
experiment of three are shown (mean ± SEM;  
*, P < 0.001). (E) CD4+ T cells from immunized SJL  
mice were primed in vitro with PLP139-151 and 
APCs in the presence of DMF or DMSO (control) 
for 1 wk, restimulated, and expanded. 107 T cells 
were transferred into syngeneic WT mice (n = 5 
per group), and EAE scores were determined. 
Data from one representative experiment of 
three are shown. Error bars represent SEM.2298 Fumarates induce protective type II DCs | Ghoreschi et al.
T cells from both groups of mice on day 42. CD4+ T cells 
from both groups of mice proliferated equally in response to 
peptide (not depicted), confirming that fumarate therapy in-
duced fully functioning Th2 cells producing elevated levels 
of IL-4 and IL-10, rather than T reg cell or CD4+ T cell de-
pletion (Fig. S7 D). We then transferred equal numbers of 
these in vivo primed T cells from both groups into naive re-
cipients. The cells from diseased mice induced severe EAE 
(Fig. 8 E). In sharp contrast, CD4+ T cells from mice immu-
nized during fumarate treatment developed a Th2 phenotype 
that failed to induce EAE in naive mice (grade ≤1; Fig. 8 E), 
directly showing that in vivo priming with the type II DCs 
abolished their capacity to cause EAE.
DISCUSSION
As DMF is one of the first small molecules effective in the 
treatment of both MS and psoriasis, analyzing the mode of 
action of fumarates should unravel key mechanisms under-
lying both diseases. It further opens a platform to search for 
Th2 cells. We first induced EAE in either WT mice or IL-4–
deficient (IL-4 KO) mice with MOG35-55 peptide and 
followed  the  course  of  disease  in  either  control  mice  or 
DMF-treated mice. Without DMF treatment, both WT as 
well as IL-4 KO mice developed severe EAE (Fig. S8 A). 
Importantly, DMF treatment protected only WT mice from 
severe encephalomyelitis, whereas DMF treatment did not 
protect mice that were deficient in IL-4 (Fig. S8 B). This di-
rectly demonstrates that clinically effective DMF required the 
induction of IL-4–producing cells to protect against EAE.
To determine whether antigen-specific Th2 cells can me-
diate this protection, we primed TCR V8.2 transgenic B10.
PL mice with myelin basic protein (MBP) Ac1-11 peptide in 
CFA. Immunization of control mice resulted in severe EAE, 
and five out of eight animals died (Fig. 8 D).
Even in the presence of an expanded number of MBP-
reactive CD4+ T cells, fumarate treatment improved EAE   
(P < 0.01 over 30 d), some mice even remained healthy (Fig. 8 D), 
and all survived. Subsequently, we isolated the transgenic   
Figure 8.  Fumarates induce type II APCs and Th2 cells in vivo and abolish the capacity of autoreactive CD4+ T cells to induce EAE. 
(A and B) SJL mice received DMF or DMF-free (control) water and were immunized with PLP139-151 peptide in CFA. On days 1–3, draining lymph nodes 
were isolated, RNA was extracted, and IL-12/IL-23p40, IL-12p35, or IL-23p19 expression (A) or Tbx21, Rorc, or Gata3 expression (B) was analyzed by  
RT-PCR (mean ± SEM; **, P < 0.001). Data were normalized to -actin levels, and expression in naive mice was set as 1.0 (gray bars). Data from one represen-
tative experiment of three are shown (*, P < 0.01). (C) SJL mice were fed with DMF-containing or -free (control) water and immunized with PLP139-151 
peptide in CFA and pertussis toxin (n = 5 per group). Clinical EAE scores were determined at the indicated times after immunization. Data are from one 
representative experiment of four. (D) TCR V8.2 transgenic B10.PL mice were fed with 5 mg MMF or MMF-free (control) water (n = 8 per group).  
Mice were then immunized with MBP Ac1-11 peptide in CFA, and clinical scores were assessed at the indicated times after immunization. EAE incidence 
was 8/8 for control mice and 6/8 in the MMF group. (E) CD4+ T cells were isolated from spleens of MMF-treated or control donors from D on day 42,  
and equal numbers of cells (107) were adoptively transferred into naive mice. EAE scores were assessed at the indicated times after adoptive transfer 
(MMF group, n = 4; control group, n = 6). Experiments with MMF were performed four times in B10.PL or SJL mice, and data shown are from one  
representative experiment. (C and E) Error bars represent SEM.JEM Vol. 208, No. 11 
Article
2299
from unprimed but either DMF-treated or control mice had 
equivalent numbers of IFN-–, IL-17–, or IL-4–producing 
CD4+ T cells after polyclonal stimulation (unpublished data). 
In sharp contrast, freshly isolated DCs from DMF-treated 
mice differed from DCs of control mice. DCs from DMF-
treated mice had increased HO-1 mRNA expression and sig-
nificantly reduced IL-12 and IL-23 mRNA expression and 
cytokine production when stimulated with LPS. Thus, DMF 
caused immune deviation in vitro and in vivo by inducing 
type II DCs. The powerful DMF-mediated suppression of 
STAT1  phosphorylation  in  DCs  provided  an  important   
link. This significance was supported by the suppression of   
ICSBP/IRF-8, an IL-12–regulating transcription factor di-
rectly downstream of IFNs and STAT1. Moreover, DCs from 
STAT1/ mice failed to produce substantial amounts of 
IL-12. As GSH-depleting small molecules as well as glatir-
amer acetate have previously been connected with STAT1 
signaling (Weber et al., 2007; Kim et al., 2008), one mode of 
inducing type II DCs with DMF may be the ROS-mediated 
prevention of STAT1 phosphorylation in APCs. However, 
STAT1/ and IL-12p35/ mice develop more severe EAE 
than WT mice (Becher et al., 2002; Bettelli et al., 2004).
As IL-23p19/ mice are resistant to EAE, prevention of 
STAT1  phosphorylation  may  suppress  IL-12  production, 
without interfering with IL-23. Indeed, DCs from STAT1/ 
mice produced normal amounts of IL-23, a finding which may 
explain the increased disease severity of EAE in STAT1/ 
mice. It further shows that DMF-mediated oxidative stress 
impairs IL-23 production and EAE through pathways differ-
ent from impaired STAT1 signaling alone.
In line with others, we found no major response of Nrf2 
mRNA to ROS (Durchdewald et al., 2007). As HO-1 is a 
classical ROS-sensitive heat shock protein (Keyse and Tyrrell, 
1989), we speculated that ROS stress should enhance TLR-
mediated induction of HO-1, a molecule associated with in-
hibition of EAE (Chora et al., 2007) and of experimental 
IBD (Hegazi et al., 2005). Indeed, DMF treatment of human 
PBMCs promotes HO-1 mRNA and protein production   
in response to TLR stimuli, and HO-1 siRNA partially re-
stores IL-12/IL-23p40 expression in DMF-treated PBMCs 
(Lehmann et al., 2007). In addition, HO-1/ mice share 
with STAT1/ or IL-12p35/ mice an exacerbated course 
of EAE (Chora et al., 2007; Tzima et al., 2009). We therefore 
hypothesized that HO-1 might negatively regulate IL-23p19. 
Indeed, HO-1 siRNA was able to restore IL-23p19 mRNA 
production  and,  partially,  IL-12/IL-23p40,  while  leaving   
IL-12p35 unaffected. In line with others (Lin et al., 2007), we 
also found that in DCs, conditions that induce HO-1 result 
in translocation of a truncated, N-terminal part of HO-1 into 
the nucleus. Interestingly, in DCs treated with DMF, nuclear 
HO-1 physically associates with AP-1– and NF-B–binding 
sites of the promoter region of IL-23p19. This is of biological 
significance, as nuclear HO-1 interferes with the transcrip-
tional activity of AP-1 and NF-B (Lin et al., 2007). In line 
with  these  studies,  we  found  that  HO-1  interacts  with   
NF-B–binding  sites  of  the  IL-23p19  promoter,  thereby   
novel therapeutic strategies. Four major conclusions result 
from our data. (1) Intracellular concentrations of GSH, the 
main intracellular ROS scavenger, determine whether im-
mune responses differentiate into either a Th1/Th17 or a 
Th2 phenotype. (2) In vitro and direct ex vivo analysis of 
DCs and T cells demonstrate that the inhibition of Th1/
Th17 cells and the induction of Th2 cells result from the in-
duction of type II DCs and not from direct modulation of   
T cell differentiation. (3) GSH depletion induces type II DCs by 
affecting  two  distinct  signaling  cascades:  induction  of  HO-1   
impairs production of IL-23, whereas silencing of STAT1   
phosphorylation impairs IL-12 production. (4) Immune de-
viation, based on the active induction of autoreactive Th2 
cells, is a valid approach for the treatment of inflammatory 
autoimmune diseases mediated by autoreactive Th1 and 
Th17 cells.
Based on the observation that different GST genotypes 
are closely associated with distinct serum IgE levels and the 
risk of ROS-triggered type I allergy on the one hand (Gilliland 
et al., 2004) and the observation that ROS stress impairs 
IL-12 production (Peterson et al., 1998) on the other, we 
hypothesized that DMF might exert the antiinflammatory   
effects by inducing type II DCs through GSH depletion.   
Depending on the experimental conditions, DMF was re-
ported to either decrease or increase GSH levels (Mrowietz 
and Asadullah, 2005). To determine the significance of 
DMF-induced GSH depletion and the resulting ROS stress 
for induction of type II DCs, we first compared DMF and 
MMF  with  H2O2  and  restored  GSH  with  GSH-OEt  or 
NAC. DMF, MMF, or H2O2 had identical effects on the cyto-
kine production by DCs (unpublished data), and the effects 
were fully reversed by GSH-OEt or NAC. Thus, GSH de-
pletion by DMF generated type II DCs that produced IL-10 
instead of IL-12 or IL-23 and that induced Th2 instead of 
Th1 and Th17 cells. Similar to DMF, another drug used for 
the treatment of MS, glatiramer acetate, can deviate Th1 into 
Th2 responses in mice and in humans. Like DMF, glatiramer 
acetate induces immune deviation by inducing type II APCs 
that subsequently favor T cell differentiation toward a Th2 
phenotype and ameliorate EAE (Weber et al., 2007). Al-
though induction of type II APCs appears to be a viable mecha-
nism for ameliorating autoimmune disease (Racke et al., 1994; 
Schuler et al., 2003; Chora et al., 2007; Weber et al., 2007), 
the underlying molecular mechanisms that result in type II 
APCs remain unclear (Kapsenberg, 2003). As various modes 
of ROS stress, including CO exposure, suppress Th1 devel-
opment without inducing T reg cells (Hegazi et al., 2005; 
Nakahira et al., 2006; Chora et al., 2007), we analyzed the 
effects of ROS on the signaling pathways that are involved   
in the differentiation of Th1, Th17, and Th2 responses. Impor-
tantly, DMF affected T-bet, ROR-t, and GATA3 only in 
CD4+ T cells stimulated by antigen and APCs. DMF had no 
effect  on  CD4+  T  cells  stimulated  with  anti-CD3/CD28 
mAb in the absence of APCs. These experimental conditions 
revealed that DMF affected T cells only indirectly. This was 
confirmed by in vivo data. Freshly isolated CD4+ T cells 2300 Fumarates induce protective type II DCs | Ghoreschi et al.
of psoriasis in humans (Ghoreschi et al., 2003b), and the 
unique efficacy of DMF and glatiramer acetate, two small 
molecules which are both effective in MS (Weber et al., 2007; 
Kappos et al., 2008), to impair IL-12 and IL-23 and, in addi-
tion, deviate Th cell responses toward a Th2 phenotype.
MATERIALS AND METHODS
Psoriasis therapy with fumarates. PBMCs were isolated from 19 patients 
studied who received DMF (720 mg/day) or placebo during a controlled, 
randomized  double-blind  trial  (FAG-201;  Fumapharm/Biogen  Idec)  for   
severe psoriasis (psoriasis area and severity index ≥ 12 at baseline). Intra-
cellular cytokine staining and flow cytometry were performed from accessible 
patient samples at the indicated time points. CD14+ monocytes from healthy 
donors were isolated by MACS separation (Miltenyi) and differentiated into 
DCs with 1,000 U/ml GM-CSF and 500 U/ml IL-4 for 7 d before activa-
tion with 1 mg/ml LPS. The study protocol, patient documentation, and 
blood analysis were approved by the ethics committees of the Eberhard Karls 
University Tübingen and the Ludwig-Maximilians University Munich.
Mice. Female BALB/c, C57BL/6, C57BL/6-Il4/, B10.PL, SJL/J, STAT1/ 
Sv129SvEv, TCR V8.2 B10.PL, and DO11.10 TCR transgenic mice were 
purchased (The Jackson Laboratory, Charles River, and Harlan-Winkelmann) 
and maintained in the animal facilities of the University of Texas South-
western Medical Center, the Ohio State University Medical Center, or the   
Eberhard Karls University Tübingen under specific pathogen-free condi-
tions. Animal experiments were approved by the Institutional Animal Care 
and Use Committee of the University of Texas Southwestern, the Ohio 
State University, or Regierungspräsidium Tübingen.
GSH determination. Cellular GSH and GSH disulfide were determined   
in microtiter plate assays using a colorimetric method (Dringen and Hamprecht,   
1996).  GSH  disulfide  was  repeatedly  not  increased  in  the  cells  exposed   
to fumarates.
Quantifying ROS. BMDCs were treated with vehicle (DMSO) alone or 
with 70 µM DMF or in combination with 1 mM GSH-OEt or with 1 mM 
NAC. After incubation for 2–4 h at 37°C, DCs were stained with 1 mM 
2’,7’dichlorofluorescein (H2DCFDA; Invitrogen) for 30 min, washed with 
PBS, and analyzed by flow cytometry (FACSCalibur; BD), using CellQuest 
(BD) and FCS Express software (De Novo Software).
Cytokine assays. ELISA sets or single components were used for quantifi-
cation of IL-4, IL-10, IL-12, and IFN- (BD), IL-23 (eBioscience), and   
IL-17 (R&D Systems). Intracellular cytokine staining was performed as de-
scribed previously (Ghoreschi et al., 2003b). Cells were stimulated with 
PMA/ionomycin or APCs/peptide. Data are presented as one representative 
of three independent experiments with similar results.
ELISPOT. CD4+ T cells from draining lymph nodes were stimulated for   
48 h with APCs and 10 µg/ml peptide in HA plates (Millipore) coated with 
10 µg/ml anti–IFN- or anti–IL-4 mAb (BD). Bound cytokines were visu-
alized by incubation with biotinylated anti–IFN- or anti–IL-4 mAb (BD), 
followed by the addition of streptavidin-AP conjugate (Boehringer Ingel-
heim) in PBS/Tween and premixed alkaline phosphatase substrate (Sigma-
Fast; Sigma-Aldrich) as described previously (Ghoreschi et al., 2003b). Spots 
were counted using a bioreader system (BIOSYS) and expressed as mean 
number of spots ± SEM of triplicate determinations. Spots were calculated 
as the difference between T cells cultured with peptide and T cells cultured 
with APCs only. Experiments were performed three times.
APCs and peptides. T cell–depleted spleen cells (APCs) or day 7 BMDCs 
were prepared as described previously (Lutz et al., 1999) and cultured either 
in medium alone with DMSO (C2H6OS), 70 µM DMF (C6H8O4; dissolved 
in DMSO), and 1 mM GSH-OEt (C12H21N3O6S; all from Sigma-Aldrich) 
directly suppressing the promoter activity of IL-23p19. In con-
trast, HO-1 does apparently not affect the binding of STAT1 
(Chora et al., 2007; Lin et al., 2007) or of IL-12p35 expres-
sion. Nonetheless, we and others (Chora et al., 2007) found 
that ROS stress simultaneously activates HO-1 and impairs 
STAT1 phosphorylation. This strongly suggests that DMF or 
other ROS-inducing molecules generate type II DCs through 
GSH  depletion  that  subsequently  impairs  the  production   
of both IL-12 and IL-23 by interfering with two indepen-
dent signaling pathways. Such type II DCs promote Th2 cells 
while impairing both Th1 and Th17 development. This may 
also explain why various molecules like glatiramer acetate 
(Weber et al., 2007), CO, or CoPPIX (Hegazi et al., 2005; 
Nakahira et al., 2006), which improve the Th1 and Th17 
cell–driven  autoimmune  diseases  EAE  or  IBD  in  mice,   
simultaneously suppress IL-12, IFN-, STAT1 phosphoryla-
tion, and IL-23. The profound effect on these two signaling 
pathways may explain the efficacy of DMF in treating EAE, 
as shown here and in a related study (Schilling et al., 2006), 
and in treating different human diseases such as MS (Kappos 
et al., 2008) and psoriasis (Altmeyer et al., 1994). In addition 
to  their  effects  on  oxidative  stress–related  pathways  in   
DCs, fumarates may influence related metabolic or signaling 
pathways in other cell types such as monocytes, neurons, or 
endothelia (Ghashghaeinia et al., 2010; Arbiser, 2011; Linker   
et al., 2011).
If targeting of the IL-12/IL-23 pathways by small GSH-
regulating molecules is effective in the treatment of different 
autoimmune diseases in mice and even in humans, one may 
ask why mAb against IL-12/IL-23p40 led to disappointing 
results in patients with MS (Segal et al., 2008). No studies 
have been performed to evaluate IL-12p35, IL-23p19, and 
IL-10 production by APCs in anti–IL-12/IL-23p40–treated 
humans and mice. Additionally, early intervention may be 
important when treating MS with anti–IL-12/IL-23p40 
antibodies. In sharp contrast, GSH depletion with the small 
molecule DMF directly inhibited IL-12p35 and IL-23p19 
and generated classical type II DCs that, like glatiramer ace-
tate, induced autoreactive Th2 cells. This is in line with the 
effects of recombinant IL-4 in attenuating delayed type 
hypersensitivity reactions in mice, such as EAE (Racke et al., 
1994), contact hypersensitivity (Biedermann et al., 2001a), or 
control of parasite infection (Biedermann et al., 2001b), or 
on psoriasis in humans (Ghoreschi et al., 2003b), where con-
tinuous supply of IL-4 significantly improved Th1/Th17 
diseases in a dose-dependent fashion. This suggests that suc-
cessful treatment of autoimmune diseases such as MS and 
psoriasis requires not only neutralization of IL-12 and IL-23 
by mAb but also the alteration of the pathogenic T cells via 
DCs. The data fit best with a model in which treatment of 
MS requires, in addition to the inhibition of IL-12 and IL-23, 
immune  deviation  and  the  active  induction  of  protective 
Th2 cells either by IL-4 (Racke et al., 1994) or by type II 
DCs. This is supported by the unique efficacy of IL-4 in the 
treatment of various inflammatory model diseases in mice 
(Racke et al., 1994; Biedermann et al., 2001a,b), the treatment JEM Vol. 208, No. 11 
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in Opti-MEM incubated at room temperature and then added to the cells as 
suggested  by  the  manufacturer.  After  24  h,  medium  was  removed,  and 
mRNA or protein analysis was performed 24–72 h after transfection.
Overexpression of HO-1. E1- and E3-deleted adenoviral vectors express-
ing EGFP or mouse HO-1–EGFP were a gift from T. Tüting (University of 
Bonn, Bonn, Germany) and J.W. Kupiec-Weglinski (University of Califor-
nia, Los Angeles, Los Angeles, CA). All recombinant adenoviruses were 
based on Ad5 and contained the transgene under the control of the CMV 
immediate–early promoter. Viruses were propagated in 293 cells, purified by 
cesium  chloride  density  gradient  centrifugation  and  subsequent  dialysis   
according to standard protocols, and stored at 70°C. Adenoviruses were added 
to DC cultures on day 8 at a multiplicity of infection of 300. Cells were   
incubated for 2 h at 37°C and 7.5% CO2 before stimulation with LPS for 1 h. 
Infection efficiency was confirmed by flow cytometry and Western blot 
analysis of HO-1.
ChIP and RT-PCR. ChIP was performed as described previously (Rothfuss 
et al., 2009). In brief, DMF-treated or control DCs were activated with 
LPS, cross-linked, harvested, and lysed by sonication. Cell lysates were 
immunoprecipitated with anti–HO-1 (Cell Signaling Technology) or anti– 
acetyl H3 (Millipore) antibodies. The eluted DNA was purified, and samples 
were analyzed by quantitative PCR. Primers were designed to amplify 150–
250-bp fragments from selected genomic regions. RT-PCR was performed 
in duplicate on each sample and input DNA using LightCycler 480 SYBR 
Green I Master mix (Roche) according to manufacturer’s instructions in a 
LightCycler 480 system (Roche). The product specificity was monitored by 
melting curve analysis, and product size was visualized on agarose gel by 
electrophoresis. Equal quantities of sample and input DNA were used for 
each real-time amplification. To account for the differences in DNA quan-
tity, for every genomic sequence studied, a Ct value was calculated for each 
sample by subtracting the Ct value of the chromatin immunoprecipitated 
sample from the Ct value obtained for the input and no antibody ChIP, re-
spectively. Calculating 2Ct yielded the relative amount of PCR product 
(relative  enrichment).  Binding  sites  for  AP-1  and  NF-B  within  the   
IL-23p19 promoter region were identified with Gene2Promoter (Genomatix). 
Primers  were  designed  with  Primer3  or  used  as  published  previously 
(Mise-Omata et al., 2007; Liu et al., 2009): AP-1 site (P1) forward, 5-CCAA-
AGAGGGAGATGATGTAGGG-3; and reverse, 5-AATCCAGCATC-
TTGTTCCCTG-3; NF-B (c-Rel) site (P2) forward, 5-GGCTCTCCA-
AAGAGGGAGAT-3;  and  reverse,  5-AAGCGGCTTCCTGATTTCTT-3;   
NF-B (RelA/c-Rel) site (P3) forward, 5-GGCTCTCCAAAGAGG-
GAGAT-3; and reverse, 5-CCACCTCCTTTGGTTCTGAG-3; and 
control forward, 5-TTGCAGAAGATGTGGGTTCA-3; and reverse, 
5-CCACTTGGAAACATGCAGTC-3.
Luciferase reporter gene assays. The p19 luciferase construct was a gift 
from  Y.  Chen  (University  of  Pennsylvania,  Philadelphia,  PA;  Carmody   
et al., 2007). RAW246.7 cells were transfected with a pGL3-Il23p19 reporter 
plasmid (bp 1180/+110 promoter fragment). After transfection with Lipo-
fectamine reagent, cells were treated with the indicated concentrations of 
DMF and activated with 100 ng/ml LPS. The cells were harvested with re-
porter lysis buffer (Promega) and assayed for luciferase activity. NIH 3T3 
cells were transfected with a pGL3-IL23p19 reporter plasmid (bp 560/+104; 
Kortylewski et al., 2009) together with the expression vectors for mouse 
p65/RelA (plasmid 20012; Addgene) and the indicated amounts of mouse 
HO-1 and pRSV-Gal. Plasmid concentrations were adjusted with empty 
expression vector to achieve equal amounts of total DNA. Transfection was 
performed using jetPEI (Peqlab) according to the manufacturer’s protocol, 
and 48 h after transfection, cells were harvested and luciferase assays were 
performed as described previously (Graupner et al., 2011). Activity of co-
transfected -galactosidase was used to normalize reporter gene induction.
Statistical analysis. We examined significance between groups using the 
two-tailed Student’s t test for paired or unpaired samples.
or 50 µM MMF (CaC10H10O8; Fumapharm). At the indicated time, cells 
were  either  directly  analyzed  for  intracellular  GSH  content  and  protein 
quantification or used for cytokine analysis or for T cell stimulation. For 
stimulation through TLR4, we incubated cells with 1 µg/ml of Escherichia 
coli  LPSs  055:B5  (Sigma-Aldrich).  OVA323–339  peptide  (ISQAVHAA-
HAEINEAGR), PLP139-151 peptide (HCLGKWLGHPDKF) and MOG35-55 
peptide (MEVGWYRSPFSRVVHLYRNGK) were purchased from EMC 
Microcollections, and MBP Ac1-11 peptide (ASQKRPSQRSK) was pur-
chased from CS Bio Company.
T cell cultures. CD4+ T cells were primed for 2 d with peptide and BMDCs 
or APCs, expanded for 7–8 d with 50 U/ml IL-2 (Chiron Therapeutics), and 
restimulated with either peptide and APCs for cytokine release into supernatants 
or with PMA/ionomycin for intracellular cytokine staining. Alternatively, puri-
fied CD4+ T cells were stimulated with plate-bound anti-CD3 mAb and 2 µg/ml 
soluble anti-CD28 mAb (BD) and expanded for 7–8 d with IL-2.
Myelin antigen–specific T cells and EAE induction. CD4+ T cells from 
spleen and lymph nodes of immunized SJL mice were stimulated with 10 µg/ml 
PLP139-151 and irradiated syngeneic APCs or DCs in the presence of DMSO 
or of 35–70 µM DMF in DMSO for 2–3 d, expanded for 1 wk with IL-2, and 
then restimulated for cytokine production. For adoptive transfer, we injected 
107 T cells, primed with either DMSO- or DMF-treated APCs, intraperitone-
ally into syngeneic naive mice and monitored EAE score (Racke et al., 1994). 
Active EAE was induced by immunization of either TCR transgenic B10.PL 
mice with 400 µg MBP Ac1-11 peptide in CFA, by subcutaneous injection of 
SJL mice with 75 µg PLP139-151 in CFA, or by subcutaneous injection of 
C57BL/6 or C57BL/6-Il4/ mice with 75 µg MOG35-55 in CFA. Mice 
received 200 ng pertussis toxin on days 0 and 2, and SJL mice received pertus-
sis toxin on day 0 only. GSH depletion was induced by feeding mice either   
5 mg MMF or 1.5 mg DMF in saline-containing water daily for 10–14 d   
as described previously (Ghashghaeinia et al., 2010). Control mice were fed 
with fumarate-free saline-containing water. Clinical assessment of EAE was 
performed using the following scale: 0, no disease; 1, limp tail; 2, hind limb 
weakness or partial paralysis; 3, complete hind limb paralysis; 4, forelimb and 
hind limb paralysis; 5, moribund state.
Gene expression analysis. Ex vivo cytokine mRNA was determined with-
out restimulation. Total RNA from indicated tissue or cells was isolated by 
standard methods and reverse transcribed. Quantitative RT-PCR was per-
formed using the LightCycler 480 and SYBR green (Roche) or TaqMan probes 
(TIB MOLBIOL). -Actin levels were measured in the same PCR reaction. 
Individual RT-PCR reactions were performed in 10-µl volumes in a 96-well 
plate. The relative gene expression of Il12p35, Il12/Il23p40, Il23p19, Rorc, 
Gata3, Tbx21, and Ho1 was calculated against the expression of -actin. Only 
samples with appropriate dissociation curves were considered for analysis.
Western blot analysis. BMDCs or the indicated cell combinations were 
incubated as given in the figure legends. Cells were washed with ice-cold 
PBS before lysates were separated by SDS-PAGE and blotted onto polyvinyl-
idenefluoride membranes. STAT1, phospho-STAT1 (Tyr701), p44/42 
MAPK, and phospho-p38 MAPK (Thr180/Tyr182) were detected with 
rabbit pAbs (dilution 1:1,000; Cell Signaling Technology) and T-bet or 
GATA3 with antibodies from Santa Cruz Biotechnology, Inc. Immunoblots 
were visualized by incubation with horseradish peroxidase–conjugated goat 
anti–rabbit IgG (dilution 1:2,000; Cell Signaling Technology) followed by 
enhanced chemiluminescence (GE Healthcare). For analysis of HO-1 ex-
pression, cell extracts were separated into nuclear or cytoplasmic fractions, 
and blots were incubated with antibodies directed against C-terminal HO-1 
(M-19; Santa Cruz Biotechnology, Inc.) or N-terminal HO-1 protein (SPA-
896; Enzo Life Sciences).
Transfection with siRNA. siRNA transfection was performed in Opti-
MEM serum-free medium (Invitrogen). To form complexes, the cationic lipid 
and siRNA (HO-1 or control; Thermo Fisher Scientific) were each diluted 2302 Fumarates induce protective type II DCs | Ghoreschi et al.
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